Tarsus Pharmaceuticals, Inc.
TARS
Classificação em ações
#4594
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Preço da ação
$71.12
Última sincronização: 2026-10-20
Valor de mercado
$3.33B
Variação (1 dia)
2.33%
Variação (1 ano)
0.42%
País
US
Negociar Tarsus Pharmaceuticals, Inc. (TARS)
Categoria
Healthcare
Rácio P/B de Tarsus Pharmaceuticals, Inc. (TARS)
Rácio P/B em October 2026 TTM: 9.05
De acordo com os relatórios financeiros mais recentes e o preço das ações da Tarsus Pharmaceuticals, Inc., o rácio P/B atual (TTM) é 9.05. No final de 2023, o rácio P/B era 3.02.
Histórico do rácio P/B da Tarsus Pharmaceuticals, Inc. de 2018 a 2026
Rácio P/B no final de cada ano
| Ano | Rácio P/B | Alterar |
|---|---|---|
| 2026 (TTM) | 9.05 | -2.40% |
| 2024 | 9.27 | 207.02% |
| 2023 | 3.02 | 61.44% |
| 2022 | 1.87 | -32.54% |
| 2021 | 2.77 | -45.19% |
| 2020 | 5.06 | -107.57% |
| 2019 | -66.86 | 2.65% |
| 2018 | -65.13 | 0.00% |
Rácio P/B de empresas semelhantes ou concorrentes
| Empresa | Rácio P/B | Diferença do rácio P/B | País |
|---|---|---|---|
| 6.251 | -30.91% |
US
|
|
| 13.2547 | 46.51% |
US
|
|
| 4.208 | -53.49% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -31.66% |
NL
|
